GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD

What Was Tested

This registered phase 2 trial tested Tirzepatide.

It had two arms (groups): COPD control (no intervention) and COPD tirzepatide treatment (active comparator).

The registry classes the interventions as drug.

More on the Plan

Obesity, which is highly prevalent among patients with COPD, further worsens these systemic manifestations through complex interactions involving inflammation, altered hormone signaling, and impaired energy metabolism.

The study will enroll 30 participants with COPD, including 20 individuals receiving tirzepatide and 10 age- and sex-matched control participants.

Participants will undergo detailed evaluations at baseline, six months, and twelve months.

These assessments will include pulmonary function testing, exercise capacity measurements, muscle strength testing, body composition analysis, imaging studies, blood biomarker analyses, and skeletal muscle biopsies.

Who Took Part

The registry lists 30 planned participants were the target.

It was open to people of any sex aged from 40 years up to 80 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age 40-80 years. Diagnosis of chronic obstructive pulmonary disease (COPD) with post-bronchodilator FEV₁/FVC \< 0.70. Former smoker with a smoking history of at least 10 pack-years. Body mass index (BMI) ≥27 kg/m² with at least one weight-related comorbidity (e.g., prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) or BMI 30-40 kg/m². Able and willing to provide written informed consent.

The full record lists 7 inclusion and 17 exclusion criteria; among the exclusions: pregnancy or breastfeeding; coagulopathy, defined as inr \> 1.4 or platelet count \<80,000/μl; active malignancy, including lung cancer.

How the Study Was Run

Design: randomized, parallel-group and open-label.

Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Nothing was hidden in this open-label Tirzepatide study: the participants and staff both knew the treatment.

It started in 2026-08-28 with completion listed for 2028-08-15.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Change in FEV1 (time frame: 12 months).

It also tracked 6 secondary outcomes, for example Change in Hand Grip Strength, Change in Six-Minute Walk Distance (6MWD), Change in Five Sit-to-Stand Performance, Change in Lean Muscle Mass, Change in Serum Leptin Concentration and Change in Skeletal Muscle Mitochondrial function.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Tirzepatide in 30 people.

Its size is small, so on its own it can only give an early look.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.